Infrequent Loss of Luminal Differentiation in Ductal Breast Cancer Metastasis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Calvo, Julia ^a   Sánchez Cid, Lourdes ^a,b,f   Muñoz, Montserrat ^a,c   Lozano, Juan José ^a,d   Thomson, Timothy M ^b,e   Fernández, Pedro L ^a,c,f  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Centre Esther Koplowitz   (Spain)

^e BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; BREAST METASTASIS; CANCER CELL; CANCER INHIBITION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS;

CARCINOMA, DUCTAL, BREAST; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84886908587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078097     Document Type: Article

References (60)

1. Visvader JE, (2009) Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 23: 2563-2577. doi:10.1101/gad.1849509. PubMed: 19933147.
2. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, (2012) WHO Classification of Tumours of the Breast, Fourth Edition. Lyon: IARC.
3. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752. doi:10.1038/35021093. PubMed: 10963602.
4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874. doi:10.1073/pnas.191367098. PubMed: 11553815.
5. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167. doi:10.1200/JCO.2008.18.1370. PubMed: 19204204.
6. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398. doi:10.1073/pnas.1732912100. PubMed: 12917485.
7. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009. doi:10.1056/NEJMoa021967. PubMed: 12490681.
8. Weigelt B, Reis-Filho JS, (2010) Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res 12 (Suppl 4)():: S5. doi:10.1186/bcr2468. PubMed: 21172089.
9. Rakha EA, Ellis IO, (2011) Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 18: 255-267. doi:10.1097/PAP.0b013e318220f5d1. PubMed: 21654357.
10. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29: 4273-4278. doi:10.1200/JCO.2010.31.2835. PubMed: 21990413.
11. Dunkler D, Michiels S, Schemper M, (2007) Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43: 745-751. doi:10.1016/j.ejca.2006.11.018. PubMed: 17257824.
12. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, et al. (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20: 3628-3636. doi:10.1200/JCO.2002.02.026. PubMed: 12202663.
13. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410. doi:10.1111/j.1365-2559.1991.tb00229.x. PubMed: 1757079.
14. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272. doi:10.1093/jnci/djj052. PubMed: 16478745.
15. Halsted WS, (1907) I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. Ann Surg 46: 1-19. doi:10.1097/00000658-190707000-00001.
16. Punglia RS, Morrow M, Winer EP, Harris JR, (2007) Local therapy and survival in breast cancer. N Engl J Med 356: 2399-2405. doi:10.1056/NEJMra065241. PubMed: 17554121.
17. Foulkes WD, Reis-Filho JS, Narod SA, (2010) Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol 7: 348-353. doi:10.1038/nrclinonc.2010.39. PubMed: 20309006.
18. Sotiriou C, Pusztai L, (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800. doi:10.1056/NEJMra0801289. PubMed: 19228622.
19. Kawada K, Taketo MM, (2011) Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res 71: 1214-1218. doi:10.1158/0008-5472.CAN-10-3277. PubMed: 21212413.
20. Nguyen DX, Bos PD, Massague J, (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284. doi:10.1038/nrc2622. PubMed: 19308067.
21. Achen MG, Stacker SA, (2008) Molecular control of lymphatic metastasis. Ann N Y Acad Sci 1131: 225-234. doi:10.1196/annals.1413.020. PubMed: 18519975.
22. Klein CA, (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9: 302-312. doi:10.1038/nrc2627. PubMed: 19308069.
23. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15. doi:10.1093/nar/gng015. PubMed: 12582260.
24. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121. doi:10.1073/pnas.091062498. PubMed: 11309499.
25. Sneath PH, Sokal RR, (1973) Numerical taxonomy: the principles and practice of numerical classification. San Francisco: W.H. Freeman.
26. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145. PubMed: 17159189.
27. Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, et al. (2010) FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development 137: 2045-2054. doi:10.1242/dev.043299. PubMed: 20501593.
28. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, et al. (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 67: 6477-6483. doi:10.1158/0008-5472.CAN-07-0746. PubMed: 17616709.
29. Hoch RV, Thompson DA, Baker RJ, Weigel RJ, (1999) GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 84: 122-128. doi:10.1002/(SICI)1097-0215(19990420)84:2. PubMed: 10096242.
30. Kong SL, Li G, Loh SL, Sung WK, Liu ET, (2011) Cellular reprogramming by the conjoint action of ERalpha, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol 7: 526. PubMed: 21878914.
31. Lacroix M, Leclercq G, (2004) About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Mol Cell Endocrinol 219: 1-7. doi:10.1016/j.mce.2004.02.021. PubMed: 15149721.
32. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, et al. (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158: 905-919. doi:10.1016/S0002-9440(10)64038-2. PubMed: 11238039.
33. Arnold A, Papanikolaou A, (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23: 4215-4224. doi:10.1200/JCO.2005.05.064. PubMed: 15961768.
34. Pastorekova S, Zatovicova M, Pastorek J, (2008) Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 14: 685-698. doi:10.2174/138161208783877893. PubMed: 18336315.
35. Xing P, Li JG, Jin F, Zhao TT, Liu Q, et al. (2011) Clinical and biological significance of hepsin overexpression in breast cancer. J Investig Med 59: 803-810. PubMed: 21383634.
36. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, et al. (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9: 201-209. doi:10.1038/ncb1530. PubMed: 17187062.
37. Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, et al. (2011) Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol 31: 4609-4622. doi:10.1128/MCB.05766-11. PubMed: 21930782.
38. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, et al. (2008) GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13: 141-152. doi:10.1016/j.ccr.2008.01.011. PubMed: 18242514.
39. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z, (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127: 1041-1055. doi:10.1016/j.cell.2006.09.048. PubMed: 17129787.
40. Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, et al. (2010) Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 41: 1794-1801. doi:10.1016/j.humpath.2010.06.010. PubMed: 21078439.
41. Gulbinas A, Berberat PO, Dambrauskas Z, Giese T, Giese N, et al. (2006) Aberrant gata-3 expression in human pancreatic cancer. J Histochem Cytochem 54: 161-169. doi:10.1369/jhc.5A6626.2005. PubMed: 16087702.
42. Rakha EA, Ellis IO, (2009) Triple-negative/basal-like breast cancer: review. Pathology 41: 40-47. doi:10.1080/00313020802563510. PubMed: 19089739.
43. Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, et al. (2013) GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum: Pathol.
44. Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, et al. (2009) Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 11: R40. doi:10.1186/bcr2327. PubMed: 19549328.
45. Ciocca V, Daskalakis C, Ciocca RM, Ruiz-Orrico A, Palazzo JP, (2009) The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol 40: 489-495. doi:10.1016/j.humpath.2008.09.010. PubMed: 19084267.
46. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, et al. (2005) Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65: 11259-11264. doi:10.1158/0008-5472.CAN-05-2495. PubMed: 16357129.
47. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. doi:10.1016/j.cell.2011.02.013. PubMed: 21376230.
48. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507. doi:10.1038/ng.127. PubMed: 18443585.
49. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, et al. (2010) Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 16: 2715-2728. doi:10.1158/1078-0432.CCR-09-1800. PubMed: 20442299.
50. de The H, Chen Z, (2010) Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 10: 775-783. doi:10.1038/nrc2943. PubMed: 20966922.
51. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R, (2010) GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 285: 14042-14051. doi:10.1074/jbc.M110.105262. PubMed: 20189993.
52. Beug H, (2009) Breast cancer stem cells: eradication by differentiation therapy? Cell 138: 623-625. doi:10.1016/j.cell.2009.08.007. PubMed: 19703390.
53. Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, et al. (2011) GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells. Oncogene 31: 2017-2027. PubMed: 21892208.
54. Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, et al. (2009) GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene 28: 2634-2642. doi:10.1038/onc.2009.126. PubMed: 19483726.
55. Pei XH, Bai F, Smith MD, Usary J, Fan C, et al. (2009) CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell 15: 389-401. doi:10.1016/j.ccr.2009.03.004. PubMed: 19411068.
56. Amsen D, Antov A, Jankovic D, Sher A, Radtke F, et al. (2007) Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 27: 89-99. doi:10.1016/j.immuni.2007.05.021. PubMed: 17658279.
57. Fang TC, Yashiro-Ohtani Y, Del Bianco C, Knoblock DM, Blacklow SC, et al. (2007) Notch directly regulates Gata3 expression during T helper 2 cell differentiation. Immunity 27: 100-110. doi:10.1016/j.immuni.2007.04.018. PubMed: 17658278.
58. van Hamburg JP, de Bruijn MJ, Dingjan GM, Beverloo HB, Diepstraten H, et al. (2008) Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes. Mol Immunol 45: 3085-3095. doi:10.1016/j.molimm.2008.03.018. PubMed: 18471881.
59. Molenaar JJ, Ebus ME, Koster J, Santo E, Geerts D, et al. (2010) Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene 29: 2739-2745. doi:10.1038/onc.2010.21. PubMed: 20154722.
60. Jiang S, Katayama H, Wang J, Li SA, Hong Y, et al. (2010) Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells. Horm Cancer 1: 11-20. doi:10.1007/s12672-010-0006-x. PubMed: 21761347.